ScreenerHero

INDV Indivior Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · indivior.com
35.99USD+0.78%Mkt Cap: 4.25B $P/E: 12.90

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap4.25B USD
Enterprise Value4.50B USD
Revenue (TTM)1.33B USD
Gross Profit993.00M USD
Net Income (TTM)210.00M USD
Revenue/Share10.78 USD
Last Price35.99 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees827
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.90
P/E (Forward)7.31
PEG—
EV/EBITDA7.82
EV/Revenue3.38
P/S3.17
P/B-20.26
EPS (TTM)2.79
EPS (Forward)4.88
52W Range
22.5666% of range42.81
52W High42.81 USD
52W Low22.56 USD
Profitability
Gross Margin80.15%
Oper. Margin46.94%
EBITDA Margin43.28%
Profit Margin16.95%
ROE-212.12%
ROA17.49%
Growth
Revenue Growth13.60%
Earnings Growth600.00%
Cash Flow & Leverage
Operating CF-27.00M USD
CapEx (TTM)67.00M USD
FCF Margin6.50%
FCF Yield2.04%
Net Debt287.00M USD
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity-3.55
Current Ratio0.83
Quick Ratio0.59
Book Value/Sh-1.76 USD
Cash/Share1.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateOct 30, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)49.00 USD
Upside (mean)+36.1%
Target Range43.00 USD – 53.00 USD
43.00+36.1% to mean53.00
# Analysts4
Ownership
Shares Out.118.03M
Float109.46M
Insiders1.80%
Institutions102.73%
Short Interest
Short Ratio5.6d
Short % Float11.25%
Short % Out.9.47%
Shares Short11.17M
Short (prev mo.)10.45M
Technical
SMA 5036.82 (-2.3%)
SMA 20035.73 (+0.7%)
Beta1.11
S&P 52W Chg14.58%
Avg Vol (30d)1.68M
Avg Vol (10d)1.63M
Technical Indicators
RSI (14)49.2
MACD-0.2471
MACD Signal-0.4361
MACD Hist.+0.1890
BB Upper36.95 USD
BB Middle35.36 USD
BB Lower33.78 USD
BB Width8.96%
ATR (14)0.9760 USD
Vol Ratio (20d)1.24x